The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Which do patients prefer as a first-line therapy, EGFR-TKI or chemotherapy, if they have NSCLC harboring EGFR mutation? A Vignettes study (LOGIK0903).
Jiichiro Sasaki
Honoraria - AstraZeneca; Chugai Pharma; Lilly; Sanofi
Research Funding - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Kyowa Hakko Kirin; Lilly; Yakult Honsha
Shoji Tokunaga
No relevant relationships to disclose
Takayuki Suetsugu
No relevant relationships to disclose
Noriyuki Ebi
No relevant relationships to disclose
Minoru Fukuda
No relevant relationships to disclose
Nobuhiko Nagata
No relevant relationships to disclose
Koichi Takayama
Honoraria - AstraZeneca; Chugai Pharma; Lilly; Pfizer
Research Funding - Chugai Pharma; Eisai; Kyowa Hakko Kirin; Taiho Pharmaceutical
Nobuko Tsuruta
No relevant relationships to disclose
Masayuki Ishida
No relevant relationships to disclose
Chinatsu Nishida
No relevant relationships to disclose
Kosuke Kashiwabara
No relevant relationships to disclose
Shinji Akamine
No relevant relationships to disclose
Kazutoshi Komiya
No relevant relationships to disclose
Noriaki Nakagaki
No relevant relationships to disclose
Hiroto Kishi
No relevant relationships to disclose
Takashi Seto
No relevant relationships to disclose
Sho Saeki
No relevant relationships to disclose
Yosuke Uchitomi
No relevant relationships to disclose
Yukito Ichinose
No relevant relationships to disclose